[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100410835":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":35,"centralContacts":39,"locations":45,"responsibleParty":63,"collaborators":65,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":10,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":10,"enrollmentInfo":78,"targetDuration":10,"studyType":81,"phases":10,"briefSummary":82,"conditions":83,"keywords":10,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort A (questionnaire, medical record review)",null,"Patients complete a QoL questionnaire at 2-4 weeks and then 6-8 weeks after portal vein stenting procedure. Patients' medical records are also reviewed.",[13,14,15],"Other: Electronic Health Record Review","Other: Quality-of-Life Assessment","Other: Questionnaire Administration",{"label":17,"type":10,"description":18,"interventionNames":19},"Cohort B (medical record review)","Patients' medical records are reviewed retrospectively.",[13],[21,25,31],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"Electronic Health Record Review","Review of medical records",[9,17],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"Quality-of-Life Assessment","Ancillary studies",[9],[30],"Quality of Life Assessment",{"type":6,"name":32,"description":33,"armGroupLabels":34,"otherNames":10},"Questionnaire Administration","Complete questionnaires",[9],[36],{"name":37,"affiliation":5,"role":38},"Joshua D Kuban","PRINCIPAL_INVESTIGATOR",[40],{"name":41,"role":42,"phone":43,"phoneExt":10,"email":44},"Joshua D. Kuban","CONTACT","713-745-0944","jdkuban@mdanderson.org",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"M D Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-95.36327,29.76328,{"lat":58,"lon":57},[61,62],{"name":41,"role":42,"phone":43,"phoneExt":10,"email":10},{"name":41,"role":38,"phone":10,"phoneExt":10,"email":10},{"type":64,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[66],{"name":67,"class":68},"National Cancer Institute (NCI)","NIH","100410835","evaluation-of-portal-vein-stenting-in-patients-with-portal-vein-stenosis-and-gastrointestinal-cancers-100410835",false,"NCT04629677","Evaluation of Portal Vein Stenting in Patients With Portal Vein Stenosis and Gastrointestinal Cancers","Prospective Evaluation of Portal Vein (PV) Stenting in Patients With PV Stenosis and Gastrointestinal Malignancies","Inclusion Criteria:\n\n* COHORT A: All patients will undergo initial staging and treatment as per the institution standard of care. Patients will be considered eligible for porto-mesenteric venous stenting (PVS) if:\n\n  * There is \\> 75% porto-mesenteric venous stenosis in either main portal vein (PV), left PV, right PV, or the superior mesenteric vein (SMV), even in absence of symptoms of portal hypertension\n  * Patients presented with any degree of vascular narrowing of said vessels and symptomatic portal hypertension including variceal bleeding, refractory ascites, abdominal pain, intestinal edema, or diarrhea after exclusion of tumor-related causes as direct tumor invasion or peritoneal dissemination\n* COHORT B: Patients who have thrombosis\u002Fstenosis of the main portal vein but who did not undergo stenting","ALL","18 Years",{"count":79,"type":80},150,"ESTIMATED","OBSERVATIONAL","This study collects information about the safety and effect of portal vein stenting in gastrointestinal cancer patients with portal vein stenosis. This study may help researchers learn how long the portal vein stays open and free from blockage and the effects of portal vein stenting on patients' overall well-being.",[84],"Malignant Digestive System Neoplasm","2026-01-08",{"date":87,"type":88},"2026-01-12","ACTUAL",{"date":90,"type":88},"2019-04-02",{"date":92,"type":80},"2026-04-30",{"name":5,"class":6},1]